Boston Therapeutics today announced positive results of a clinical study of its SUGARDOWN® product, a non-systemic chewable dietary supplement tablet designed to reduce the spike in post-meal blood glucose. SUGARDOWN is designed to be taken before meals to block the action of carbohydrate-hydrolyzing enzymes, which break down carbohydrates into glucose and release them into the bloodstream.
Conducted at the University of Sydney in Australia, the clinical trial showed that the post-meal incremental area under the curve (iAUC) for glucose and insulin were significantly lower following consumption of SUGARDOWN prior to a high carbohydrate meal of rice in a dose-dependent manner.
SUGARDOWN was tested at two doses in 10 healthy, non-smoking subjects, resulting in a reduction of up to 61 percent in post-meal elevation of blood glucose compared with the rice consumed alone. On average, there was a 32 percent reduction in the post-meal iAUC for glucose and a 24 percent reduction in post-meal insulin.
“These study results demonstrate that SUGARDOWN dietary supplement tablets can have a significant effect in reducing post-meal glucose and insulin responses,” David Platt, Ph.D., CEO of Boston Therapeutics stated in the press release. “Such a nutritional approach may be valuable in the management of blood sugar and could enhance the role of functional dietary supplements as part of a diabetes management plan.”
Boston Therapeutics reports that no severe adverse effects were reported or observed during the study.
For more information visit www.bostonti.com
Let us hear your thoughts below:
